1. Opening Hook
Remember when medtechs bragged about “organic” growth? Poly Medicure decided that was boring and went full M&A surgeon mode. Two new European patients—Citieffe (Italy, ortho trauma) and PendraCare (Netherlands, cardio catheters)—just joined the Polymed hospital ward. The bill? ₹280 crore in new revenue and some mild margin anesthesia. Himanshu Baid called it “synergy,” but investors might call it “integration rehab.” The company also launched an AI-driven training program—because apparently even their sales reps need machine learning to sell faster.
Stick around—this call had everything: FDA fights, CE marks, tariff tantrums, and 2,000 cardiac stent trials that sound like the script for “Operation Margin Recovery.”
2. At a Glance
- Revenue up 5.7% YoY (₹444 cr): CFO swears no accounting yoga, just real growth.
- EBITDA ₹119 cr (26.8% margin): Flatlining slightly—acquisition hangover visible.
- PAT ₹92 cr: A polite 4.5% jump—steady as a surgeon’s hand.
- Domestic growth 17%: India’s heartbeat strong; private hospitals led the charge.
- International growth 9% QoQ: Europe coughed, but Africa & Asia prescribed recovery.
- Gross margin 69.4%: Almost 70%—no med-device discounting here.
- Cash ₹1,109 cr: CFO flexed liquidity like a hospital with a private oxygen plant.
3. Management’s Key Commentary
“We’ve acquired Citieffe and PendraCare, adding ₹280 crores annual revenue.”
(Translation: Why grow 5% when you can buy 10%?)
“PACE and SARATHI platforms will train teams with AI-powered modules.”
(Because even medtech sales now need ChatGPT for charm 😏)
“Domestic business up 18%; government sales down 14%.”
(Tender business dumped—too many forms, too few profits.)
“International markets recovering; Europe down 9.6%, but sequentially improving.”
(Basically: Europe’s not dead yet—just on IV fluids.)
“Renal segment up 18%, impacted by GST chaos.”
(India’s favorite plot twist—taxes struck again.)
“Two new plants under construction; CAPEX ₹250 crores this year.”
(If revenue doesn’t grow, at least the factory count will.)
“PAT ₹185 crores in H1, margins at 20%.”
(
